| Expression pattern: |
UP |
| Associated gene: |
EIF4A3, IGF2BP2, CPPED1, CDK1 pre-mRNA, PI3K, AKT |
| Associated microRNA: |
- |
| Biological function: |
circCDK1 promotes LSCC cell proliferation, migration, invasion and metastasis in vitro and in vivo. |
| Molecular mechanism: |
EIF4A3 induces circCDK1 biogenesis by binding flanking regions of CDK1 pre-mRNA; circCDK1 binds IGF2BP2, is exported to the cytoplasm, competitively blocks IGF2BP2-mediated m6A modification of CPPED1, reduces CPPED1 mRNA stability, and activates the PI3K/AKT pathway. |
| Biological pathway or process: |
PI3K/AKT (promotes); proliferation (promotes); migration (promotes); invasion (promotes); metastasis (promotes); m6A modification (inhibits); mRNA stability (inhibits) |
| Detected method: |
Q
M
|
| Validation methods: |
Microarray; RT-qPCR; Clinical Sample Validation; Back-Splice Junction PCR / divergent primers PCR; RNase R Treatment; Sanger Sequencing; Nuclear-Cytoplasmic Fractionation; ISH (In Situ Hybridization); Transfection; Colony Formation Assay; Transwell Assay; In Vivo Animal Model; RIP (RNA Immunoprecipitation); RNA Pull-Down; MeRIP / MeRIP-seq; Actinomycin D / DRB Stability Assay; Western Blot; Survival Analysis; Bioinformatics Analysis |
| Clinical significance: |
High circCDK1 expression is associated with poor prognosis and unfavorable 5-year overall survival, and circCDK1 may serve as a diagnostic and prognostic marker or therapeutic target for LSCC. |
| Description: |
circCDK1 is up-regulated in LSCC tissues and cell lines and is associated with poor patient prognosis. EIF4A3 promotes its biogenesis, and circCDK1 binds IGF2BP2 to block IGF2BP2-mediated m6A modification of CPPED1, reducing CPPED1 stability and activating PI3K/AKT signaling. Functionally, circCDK1 promotes LSCC proliferation, migration, invasion and metastasis, suggesting diagnostic, prognostic and therapeutic potential. |
| Confidence score: |
0.8809 |